Biotech Billionaire's Bold Bets on Weight-Loss Drugs

Kiran Mazumdar-Shaw, a self-made female billionaire and founder of Biocon, is making strategic moves in the pharmaceutical industry, focusing on biosimilars and affordable therapies. Her company, Biocon, established in 1978, has built a reputation for producing low-cost diabetes and cancer treatments.

Biocon is now poised to enter the growing market for weight-loss drugs, anticipating a shift in healthcare needs as global patents expire. Mazumdar-Shaw sees a significant opportunity in diabetes care, particularly as Western companies pivot towards obesity treatments.

Despite facing gender bias early in her career and personal tragedies, Mazumdar-Shaw has become a prominent voice in Indian business. She is also a vocal critic of Bengaluru's infrastructure issues, advocating for proactive development.

Biocon's success, including a public float in 2004, has cemented Mazumdar-Shaw's status. She continues to lead with a philanthropic vision and a commitment to advancing healthcare solutions, even as she contemplates succession plans.